Bolt Biotherapeutics (NASDAQ:BOLT) Releases Quarterly Earnings Results, Meets Expectations

Bolt Biotherapeutics (NASDAQ:BOLT) posted its quarterly earnings results on Monday. The company reported ($0.38) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.38), Zacks reports. Bolt Biotherapeutics had a negative net margin of 665.56% and a negative return on equity of 69.46%.

Bolt Biotherapeutics Trading Down 0.3 %

Shares of BOLT stock traded down $0.00 during trading hours on Monday, reaching $0.44. The company had a trading volume of 97,537 shares, compared to its average volume of 170,092. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.16 and a quick ratio of 3.16. Bolt Biotherapeutics has a 1-year low of $0.38 and a 1-year high of $1.56. The company has a 50 day moving average of $0.48 and a 200 day moving average of $0.56. The firm has a market cap of $16.75 million, a price-to-earnings ratio of -0.26 and a beta of 0.94.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.